Droxidopa / Pyridostigmine in Orthostatic Hypotension
Status:
Completed
Trial end date:
2021-01-19
Target enrollment:
Participant gender:
Summary
The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural
transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE).
This combination should result in enhanced orthostatic release of NE. The investigators have
already demonstrated that pyridostigmine does not raise supine blood pressure.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)